BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BH-30643 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BH-30643\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06706076-2391@assetmemo.bio
DTSTAMP:20261121T005848Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:BH-30643: Phase 1/2 readout est. (NCT06706076)
DESCRIPTION:BH-30643\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harb
 oring EGFR and/or HER2 Mutations\nEstimated primary completion: 31 January
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/bh-30643#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06706076
URL:https://assetmemo.bio/drug/bh-30643#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
